Imatinib D8 structure
|
Common Name | Imatinib D8 | ||
|---|---|---|---|---|
| CAS Number | 1092942-82-9 | Molecular Weight | 501.65200 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C29H23D8N7O | Melting Point | 96-100 °C | |
| MSDS | N/A | Flash Point | N/A | |
Use of Imatinib D8Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2]. |
| Name | N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-4-[(2,2,3,3,5,5,6,6-octadeuterio-4-methylpiperazin-1-yl)methyl]benzamide |
|---|---|
| Synonym | More Synonyms |
| Description | Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2]. |
|---|---|
| Related Catalog | |
| References |
| Melting Point | 96-100 °C |
|---|---|
| Molecular Formula | C29H23D8N7O |
| Molecular Weight | 501.65200 |
| Exact Mass | 501.30900 |
| PSA | 86.28000 |
| LogP | 4.61210 |
| Hazard Codes | Xi |
|---|
| STI 571 |
| Imatinib-d8 |
| [2H8]-Imatinib |
| Benzamide,4-[(4-methyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl] |
| 4-(4-methyl-[2,2,3,3,5,5,6,6-D8]piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide |